Aspirin for Primary Prevention

May 6, 2022 Andrew To

Aspirin use in primary prevention is controversial, contrasting that of secondary prevention. It may offer benefit in some, but for most, risk-benefit analysis may argue against its use. Here is the discussion.

Duration of anti-platelets – a 2018 update

April 22, 2018 Andrew To

Cumulative Incidence of Major Adverse Cardiovascular and Cerebrovascular Events, According to Study Group. DAPT trial

64F presented with chest pain, consistent with non-ST elevation myocardial infarction with preserved systolic function. At invasive angiogram, right coronary artery was successfully stented with a drug eluting stent. On hospital discharge, she was given Aspirin, Ticagrelor as dual anti-platelet agents. How long should the dual antiplatelet therapy be continued for?

Dual anti-platelet therapy and non-cardiac surgery

March 14, 2016 Andrew To

A 75-year-old male is now 7-month post anterior myocardial infarction. He had successful proximal LAD drug eluting stent, currently on Aspirin and Ticagrelor. He is awaiting total hip joint replacement, and the orthopaedic surgeon would like to know whether he could stop his anti-platelets.